|Bid||10.41 x 3100|
|Ask||10.42 x 1800|
|Day's Range||10.34 - 10.82|
|52 Week Range||7.11 - 14.62|
|Beta (5Y Monthly)||1.54|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2020 - Mar 01, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.04|
Amicus Therapeutics (FOLD), a global, patient centric biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today provided its full-year 2020 strategic outlook and financial guidance.
2018's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the […]
Amicus Therapeutics (FOLD), a global, patient dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced preliminary 2019 revenue and Galafold (migalastat) commercial updates. This reflects the strong continued adoption of this novel precision medicine for Fabry patients with amenable mutations as well as the 90%+ continued adherence and compliance rates seen with patients.
Amicus Therapeutics (FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced clinical, regulatory and manufacturing advancements for AT-GAA, its investigational therapy for Pompe disease. Pompe disease is an inherited lysosomal disorder caused by an enzyme deficiency that leads to accumulation of glycogen (disease substrate) in cells and is characterized by severe muscle weakness that worsens over time.
By buying an index fund, you can roughly match the market return with ease. But if you buy good businesses at...
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
Yet another company wants to secure office space in Lake Nona, the fast-growing southeast Orlando suburb. Miami-based Pipeline Orlando LLC is in talks with Lake Nona developer Tavistock Development Co.
A land deal between Lake Nona's developer and a New Jersey biotech firm sets the stage for the latter company to bring new high-wage jobs and commercial development to southeast Orlando. Cranbury, New Jersey-based tech and biopharmaceutical company Amicus Therapeutics Inc. (Nasdaq: FOLD) bought 5.2 acres for $3.1 million, or roughly $596,153 an acre, in Lake Nona's 650-acre Medical City, according to Orange County records. Orlando-based Tavistock Development Co.'s Lake Nona Land Co. LLC was the seller.
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 25.00% and 1.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
3Q19 Galafold® (migalastat) Revenue of $48.8M and 1,000+ Patients on Therapy Reflects Continued Strong Global Uptake Reiterating Upwardly Revised FY19 Revenue.
PCTEL's (PCTI) third-quarter performance is likely have benefited from the demand for 5G scanning receivers and Industrial IoT antenna project wins.
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the third quarter driven by clinical studies on its lead pipeline candidate, Zygel.